Title |
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
|
Institution |
UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX
|
Principal Investigator |
BRUGAROLAS, JAMES
|
NCI Program Director |
Kuzmin
|
Cancer Activity |
Translation Research (formerly Organ Systems)
|
Division |
DCTD
|
Funded Amount |
$2,300,000
|
Project Dates |
08/01/2016 - 07/31/2021
|
Fiscal Year |
2018
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Childhood Cancers (14.0%)
Metastasis (35.0%)
Nuclear Magnetic Resonance Imaging (NMR) (20.0%)
|
Kidney Cancer (100.0%)
Kidney Disease (100.0%)
Wilm's Tumor (14.0%)
|
Research Type |
Cancer Initiation: Alterations in Chromosomes
Cancer Progression & Metastasis
Resources & Infrastructure Related to Biology
Technology and/or Marker Testing in a Clinical Setting
Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
Systemic Therapies - Clinical Applications
Resources and Infrastructure Related to Treatment and the Prevention of Recurrence
|
Abstract |
DESCRIPTION (provided by applicant): Kidney cancer is one of the top ten most common cancers in the U.S. and is particularly prevalent in Texas. Consistent with the stated SPORE purpose, our objective is to develop a thriving infrastructure supporting """"state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment"""" of kidney cancer (both adult and pediatric). At UT Southwestern Medical Center (UTSW), we believe that outstanding basic science sets the foundation for outstanding translation. UTSW investigators have made seminal discoveries in kidney cancer, including (i) the discovery of the gene encoding HIF -2? - the main driver of lear-cell renal cell carcinoma (ccRCC); (ii) the development of a highly specific first-in-class inhibitr of the HIF-2 transcription factor, traditionally considered """"undruggable""""; (iii) the identificationof mutations in the BAP1 gene in ccRCC; (iv) the establishment of the first molecular genetic classification of sporadic ccRCC; (v) the discovery of a novel familial kidney cancer syndrome; (vi) the development of novel non-invasive tools for imaging tumor metabolism in patients; and (vii) the discovery of DROSHA mutations in Wilms tumors. These and other exciting discoveries were the basis of a Kidney Cancer Program (KCP; http://www.utsouthwestern.edu/research/kidney-cancer/index.html) involving over 70 UTSW faculty. This SPORE contains four projects: Project 1: Targeting HIF-2 for the treatment of clear-cell renal cell carcinoma; Project 2: Evaluation of the functional and clinical significance of the novel tumor suppressor gene BAP1; Project 3: Clinically actionable biomarkers from renal cell carcinoma metabolism and imaging; and Project 4: Prognostic significance and therapeutic potential of DROSHA mutations in Wilms tumor. They are supported by an Administrative Core (Core A) and three other cores: Core B - an innovative """"Biospecimen and Pathology Resources Core"""" with a live BioBank; Core C - a """"Data Analytics Core"""" supporting a pioneering web-tool linking samples to clinical information and integrated genomics; and Core D - an outstanding """"Translational Imaging Core"""" built around tools developed to study kidney cancer. A Developmental Research Program and a Career Enhancement Program thrive upon the wide scope of kidney cancer research at UTSW illustrated by the 19 LOIs with kidney-cancer relevant preliminary data submitted. Our Patient Advocate Program is comprised of six patient advocates including both experienced advocates as well as members of our kidney cancer community. The projects outlined illustrate how rigorous basic research using cellular, molecular, structural, biochemical, and genetic experimental approaches has increased our knowledge of kidney cancer, and is impacting the clinic. In summary, this Kidney Cancer SPORE represents a multidisciplinary effort from talented basic scientists, physician-scientists, and clinicians that synergistically leverages the strengths and resources we have developed in the Kidney Cancer Program to advance kidney cancer translational research, with the ultimate goal of improving kidney cancer patient outcomes." |